Pharmacy association ABDA criticizes government's drug supply law

Germany's national association of pharmacists, ABDA, has criticized a draft law proposed by Health Minister Karl Lauterbach, intended to combat drug shortages and improve supply security. ABDA stated that the draft law fails to meet expectations and instead further weakens pharmacies across the country, which are already struggling with persistent supply chain issues.

In an open letter, the president of ABDA expressed shock and disappointment with the legislative proposal, arguing it does not offer effective solutions to the drug shortage crisis. Particular criticism is directed at the proposed compensation of 50 cents for pharmacies' efforts in managing drug substitutions and supply problems. ABDA contends this amount is insufficient to cover the actual workload, which includes sourcing alternatives, consulting with doctors, and providing patient counseling.

The association emphasized that pharmacies have demonstrated their responsibility and capability in managing drug shortages, but the draft law fails to grant them necessary decision-making powers or adequate recognition. ABDA is calling on the government to strengthen pharmacies and ensure long-term drug availability. The association also pointed out that the proposal contradicts coalition agreement goals to support local pharmacies.

Furthermore, ABDA highlighted concerns about a potential regulatory gap as the SARS-CoV-2 drug supply ordinance (AMVVO) is set to expire on April 7th. According to ABDA, the ordinance's flexible substitution rules have proven effective and reduced bureaucracy. The association is urging for these rules to be permanently incorporated into law, enabling pharmacies to continue ensuring patient treatment and preventing overburdening of medical practices.